Neuroradiologic Pearls for Neuro-oncology

CONTINUUM Lifelong Learning in Neurology

Volumn 23, Issue 6, Neuro-oncology, 2017, Pages 1619-1634

  Klein, Joshua P ^a   Dietrich, Jorg ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CENTRAL NERVOUS SYSTEM TUMOR; DIAGNOSTIC IMAGING; HUMAN; NEUROIMAGING; NEURORADIOLOGY; REVIEW; TUMOR GROWTH; PROCEDURES; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM NEOPLASMS; DIAGNOSTIC IMAGING; HUMANS; TREATMENT OUTCOME;

EID: 85037118011     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000543     Document Type: Review

References (37)

1. Dietrich J Klein JP. Imaging of cancer therapy-induced central nervous system toxicity. Neurol Clin 2014; 32 (1): 147-147. doi:10.1016/j.ncl.2013.07.004.
2. Soussain C Ricard D Fike JR. CNS complications of radiotherapy and chemotherapy. Lancet 2009; 374 (9701): 1639-1651. doi:10.1016/S0140-6736(09)61299-X.
3. Dhermain FG Hau P Lanfermann H. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010; 9 (9): 906-920. doi:10.1016/S1474-4422(10)70181-2.
4. Arrillaga-Romany IC Dietrich J. Imaging findings in cancer therapy-Associated neurotoxicity. Semin Neurol 2012; 32 (4): 476-486. doi:10.1055/s-0032-1331817.
5. Bitar R Leung G Perng R. MR pulse sequences: what every radiologist wants to know but is afraid to ask. Radiographics 2006; 26 (2): 513-537. doi:10.1148/rg.262055063.
6. Neil JJ. Diffusion imaging concepts for clinicians. J Magn Reson Imaging 2008; 27 (1): 1-7.
7. Santhosh K Kesavadas C Thomas B. Susceptibility weighted imaging: A new tool in magnetic resonance imaging of stroke. Clin Radiol 2009; 64 (1): 74-83. doi:10.1016/j.crad.2008.04.022.
8. Roongpiboonsopit D Kuijf HJ Charidimou A. Evolution of cerebral microbleeds after cranial irradiation in medulloblastoma patients. Neurology 2017; 88 (8): 789-796. doi:10.1212/WNL.0000000000003631.
9. Patel P Baradaran H Delgado D. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: A systematic review and meta-Analysis. Neuro Oncol 2017; 19 (1): 118-127. doi:10.1093/neuonc/now148.
10. Chao ST Suh JH Raja S. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001; 96 (3): 191-197. doi:10.1002/ijc.1016.
11. Dunet V Pomoni A Hottinger A. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-Analysis. Neuro Oncol 2016; 18 (3): 426-434. doi:10.1093/neuonc/nov148.
12. Horská A Barker PB. Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin N Am 2010; 20 (3): 293-310. doi:10.1016/j.nic.2010.04.003.
13. Al-Okaili RN Krejza J Woo JH. Intraaxial brain masses: MR imaging-based diagnostic strategy-initial experience. Radiology 2007; 243 (2): 539-550. doi:10.1148/radiol.2432060493.
14. Delattre JY Krol G Thaler HT Posner JB. Distribution of brain metastases. Arch Neurol 1988; 45 (7): 741-744. doi:10.1001/archneur.1988.00520310047016.
15. Ellingson BM Lai A Harris RJ. Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol 2013; 34 (3): 533-540. doi:10.3174/ajnr.A3253.
16. Barami K Sloan AE Rojiani A. Relationship of gliomas to the ventricular walls. J Clin Neurosci 2009; 16 (2): 195-201. doi:10.1016/j.jocn.2008.03.006.
17. Dietrich J Imitola J Kesari S. Mechanisms of disease: The role of stem cells in the biology and treatment of gliomas. Nat Clin Pract Oncol 2008; 5 (7): 393-404. doi:10.1038/ncponc1132.
18. Omuro AM Leite CC Mokhtari K Delattre JY. Pitfalls in the diagnosis of brain tumours. Lancet Neurol 2006; 5 (11): 937-948. doi:10.1016/S1474-4422(06)70597-X.
19. Cha S. Neuroimaging in neuro-oncology. Neurotherapeutics 2009; 6 (3): 465-477. doi:10.1016/j.nurt.2009.05.002.
20. Lucchinetti CF Gavrilova RH Metz I. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008; 131 (pt 7): 1759-1775. doi:10.1093/brain/awn098.
21. Masdeu JC Quinto C Olivera C. Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology 2000; 54 (7): 1427-1433. doi:10.1212/WNL.54.7.1427
22. Provenzale JM Mukundan S Barboriak DP. Diffusion weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 2006; 239 (3): 632-649. doi:10.1148/radiol.2393042031.
23. Hu LS Baxter LC Smith KA. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009; 30 (3): 552-558. doi:10.3174/ajnr.A1377.
24. Dietrich J Monje M Wefel J Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008; 13 (12): 1285-1295. doi:10.1634/theoncologist.2008-0130.
25. Dhermain F Barani IJ. Complications from radiotherapy. Handb Clin Neurol. 2016; 134: 219-234. doi:10.1016/B978-0-12-802997-8.00013-X.
26. Brandsma D Stalpers L Taal W. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9 (5): 453-461. doi:10.1016/S1470-2045(08)70125-6.
27. Sanghera P Perry J Sahgal A. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 2010; 37 (1): 36-42. doi:10.1017/S0317167100009628.
28. Hygino da Cruz LC Jr Rodriguez I Domingues RC. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011; 32 (11): 1978-1985. doi:10.3174/ajnr.A2397.
29. Rahmathulla G Marko NF Weil RJ. Cerebral radiation necrosis: A review of the pathobiology, diagnosis and management considerations. J Clin Neurosci 2013; 20 (4): 485-502. doi:10.1016/j.jocn.2012.09.011.
30. Bobek-Billewicz B Stasik-Pres G Majchrzak H. Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. Folia Neuropathol 2010; 48 (2): 81-92.
31. Black DF Bartleson JD Bell ML Lachance DH. SMART: stroke-like migraine attacks after radiation therapy. Cephalalgia 2006; 26 (9): 1137-1142. doi:10.1111/j.1468-2982.2006.01184.x.
32. Olsen AL Miller JJ Bhattacharyya S. Cerebral perfusion in stroke-like migraine attacks after radiation therapy syndrome. Neurology 2016; 86 (8): 787-789. doi:10.1212/WNL.0000000000002400.
33. Galloway TJ Indelicato DJ Amdur RJ. Second tumors in pediatric patients treated with radiotherapy to the central nervous system. Am J Clin Oncol 2012; 35 (3): 279-283. doi:10.1097/COC.0b013e318210f533.
34. Deprez S Amant F Smeets A. Longitudinal assessment of chemotherapy induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 2012; 30 (3): 274-281. doi:10.1200/JCO.2011.36.8571.
35. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008; 29 (6): 1036-1042. doi:10.3174/ajnr.A0928.
36. Bartynski WS Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2007; 28 (7): 1320-1327. doi:10.3174/ajnr.A0549.
37. Cai X Bhattacharyya S Plitt A. Management of posterior reversible encephalopathy syndrome induced by carfilzomib in a patient with multiple myeloma. J Clin Oncol 2016; 34 (2): e1-e5. doi:10.1200/JCO.2013.49.6166.